Leslie Benet, PhD

InstitutionUniversity of California San Francisco
Address533 Parnassus Ave, UC Hall
San Francisco CA 94143
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPh.D.1965 Graduate Division (Pharmaceutical Chemistry)
    Collapse Awards and Honors
    American Pharmacists Association Academy of Pharmaceutical Research and Science (APhA-APRS),20132013 APhA-APRS Ebert Prize
    American Association of Pharmaceutical Scientists2013AAPS Journal Manuscript Award for the Most Outstanding Manuscript
    International Pharmaceutical Federation, The Netherlands2012Honorary Member
    University of Michigan2011Doctor of Science, honoris causa
    National Research Council 2011Named “National Associate”
    American College of Clinical Pharmacology, 40th Annual Meeting, Chicago, IL 2011Distinguished Investigator Award
    Controlled Release Society 2010Elected Fellow
    Catholic University of Leuven, Leuven, Belgium 2010Doctor of Philosophy, honoris causa
    American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, Georgia 2010Oscar B. Hunter Memorial Award in Therapeutics
    100th Anniversary of the Nobel Prize Awarded to Paul Ehrlich, Nürnberg, Germany2008Paul Ehrlich Magic-Bullet Award 2008 Lifetime Achievement
    University of California San Francisco2007UCSF 7th Distinguished Clinical Research Lecturer
    Institute for Scientific Information2003ISI Highly Cited Researcher
    of Medical Countermeasures Against Biological Warfare Agents 2002  - 2004Chair, IOM/NRC Committee on Accelerating the Research, Development and Acquisition
    International Pharmaceutical Federation2001Høst-Madsen Medal
    Sichuan University, Sichuan Province, China2014  - 2019Guest Professorship
    Zhengzhou University, Henan Province, China2012Visiting Professor of the First Clinical Medical College of Zhengzhou University, and the Institute
    University of Wisconsin2013Busse Lecture
    NRPB – AAPS Workshop on Clinical and Diagnostic Biomarkers, Taipei, Taiwan2012Invited Keynote Lecture
    Texas Tech University Health Science Center School of Pharmacy Research Days, Texas Tech University2012Invited Keynote Lecture
    Chinese Society of Clinical Pharmacy, Zhengzhou, China2012Honorary Member
    CPSA Shanghai 2012: From Bench to Decision Making – From Basics to Applications, Shanghai, China 2012Invited Plenary Lecture
    International Symposium on Past, Present and Future Molecular Pharmacokinetics, Tokyo, Japan 2012Invited Plenary Lecture
    Horace Rackham School of Graduate Studies, University of Michigan2011Inaugural Albert B. Prescott Distinguished Lecture
    State University of New York at Buffalo2011Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences
    Biomedical Centre, Uppsala University, Uppsala, Sweden 2011Invited Plenary Lecture, Symposium
    AstraZeneca Research & Development Mölndal, Sweden 2011The AstraZeneca Drug Hunting Lecture
    Thompson Reuters Highly Cited Researcher20141 of 16 pharmacologists worldwide to be listed in both 2001 and 2014 compilations
    2010 Pharmaceutical Sciences World Congress and the AAPS Annual Meeting and Exposition, New Orleans,2010Invited Plenary Lecture
    The 42nd Annual Pharmaceutics Graduate Student Research Meeting (PGSRM), The Ohio State University2010Invited Keynote Lecture
    18th International Symposium on Microsomes and Drug Oxidations, Beijing, China 2010Invited Plenary Lecture
    129th Annual Meeting of the Pharmaceutical Society of Japan, Kyoto, Japan 2009Invited Plenary Lecture
    University of Athens, Greece 2005Doctor of Philosophy, honoris causa
    9th International Symposium of the Controlled Release Society Indian Chapter, Mumbai, India2009Invited Plenary Lecture
    100th Anniversary of School of Pharmacy, NDMC; 2008 PST & TSHP Joint International Conference2008Invited Keynote Speaker
    2008National Defense Medical Center, Taipei
    2008Nagai Foundation Tokyo Distinguished Lectureship 2008
    28th Annual Meeting of the Japanese Society for Drug Delivery Systems, Tokyo, Japan2008Invited Plenary Lecture
    Modified Release Forum, West Point, PA 2008Invited Plenary Lecture
    109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics2008Invited Featured Speaker
    iMED.UL (Research Institute for Medicines and Pharmaceutical Sciences) University of Lisbon, Portuga2008Chair, Scientific Advisory Board
    8th International Symposium on Advances in Technology & Business Potential of New Drug Delivery Syst2008Keynote Lecture
    Japan Society for the Study of Xenobiotics, Sendai, Japan 2007International Honorary Member
    University of Michigan College of Pharmacy, Ann Arbor, MI 2007Graduation Speaker
    Division of Biocomputing, School of Medicine, University of New Mexico2007Keynote Lecture, Biocomputing Day
    Meeting of the European Drug Absorption Network, Leuven, Belgium 2007Keynote Lecture
    7th International Symposium on Advances in Technology and Business Potential of New Drug Delivery Sy2007Plenary Lecture
    4th International COE Symposium, Target Validation, Lead Optimization & Clinical Development, Tokyo2006Plenary Lecture
    16th International Symposium on Microsomes and Drug Oxidation, Budapest2006Plenary Lecture
    Gordon Research Conference on Drug Metabolism, Plymouth, NH 2006Chair
    Great Lakes Symposium 2006, Buffalo, NY 2006Keynote Address
    Journees Galeniques de Saint-Remy de Provence, Saint-Remy, France 2006Plenary Lecture
    Canadian Society for Pharmaceutical Sciences 9th Annual International Symposium on Pharmaceutical Sc2006Plenary Lecture
    Analytica Conference 2006, Munich, Germany 2006Plenary Lecture
    British Pharmaceutical Conference, Manchester, UK 2005Keynote Address
    2nd International Symposium on Scientific & Regulatory Aspects of Dissolution & Bioequivalence2005Plenary Lecture
    9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology2005Plenary Lecture
    Controlled Release Society 2004 Annual Meeting & Exposition2004Career Achievement Award in Oral Drug Delivery
    Pharmaceutical Sciences World Congress 2004, Kyoto2004Research Achievement Award in Pharmaceutical Sciences
    Romanian Academy of Medical Sciences2003Invested as a “Member of Honour”
    First Congress of the Portuguese Society for Pharmaceutical Sciences2003Opening Plenary Lecture
    International Pharmaceutical Technology Symposium 2002, Istanbul, Turkey 2002Plenary Lecture
    Academia de Ciencias Farmacéuticas de Chile, Santiago, Chile 2002Invested as a “Miembro Honorario”
    10th International Conference on Pharmaceutical Technology, Florence, Italy 2002Plenary Lecture
    American Association of Indian Pharmaceutical Scientists2001Elected Fellow
    FDA/CDER and ASCPT2015William B. Abrams Lectureship
    Medical Technology Schools2015Listed among "25 Top Pharmacy Professors" in the U.S.A.
    Thomson Reuters2014Highly cited Researcher-Pharmacology
    Medical Technology Schools2015"25 Top Pharmacy Professors" in USA
    FDA/CDER and American Society for Clinical Pharmacology and Therapeutics2015William B. Abrams Lectureship
    International Society for the Study of Xenobiotics2015North American Scientific Achievement Award
    American Pharamacists Association2016Remington Honor Medal
    University of Lisbon, Portugal2016Doctor of Philosophy, honoris causa

    Collapse Overview 
    Collapse Overview
    Dr. Benet, Professor and former Chairman (1978-1998), Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, received his A.B. (English), B.S. (Pharmacy), M.S. from the University of Michigan and Ph.D. from the University of California. He has received nine honorary doctorates: Uppsala University, Sweden (Pharm.D., 1987), Leiden University, The Netherlands (Ph.D., 1995), University of Illinois at Chicago (D.Sc., 1997), Philadelphia College of Pharmacy and Science (D.Sc., 1997), Long Island University (D.Sc., 1999), University of Athens, Greece (Ph.D., 2005), Catholic University of Leuven, Belgium (Ph.D., 2010), University of Michigan (D.Sc., 2011) and Universidade de Lisboa, Lisbon, Portugal (Ph.D., 2016). His research interests, more than 570 publications, 6 books and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. Dr. Benet is listed by Thompson Reuters as one of the most highly cited pharmacologists worldwide, with his published peer-reviewed papers cited more than 20,000 times. His most recent work has addressed the interplay of metabolic enzymes and transport proteins as related to oral bioavailability and hepatic elimination, and the development of the Biopharmaceutics Drug Disposition Classification System (BDDCS). Dr. Benet was a Founder/Editor of the JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS (1973-98) and Associate Editor of PHARMACOLOGY AND THERAPEUTICS (1995-2000). He presently serves a member of the Editorial boards of PHARMACOLOGY, CHEMICAL AND PHARMACEUTICAL BULLETIN, AAPS JOURNAL and ARCHIVES OF DRUG INFORMATION. He is a Fellow of the Academy of Pharmaceutical Sciences and Research, the American Association of Pharmaceutical Scientists (AAPS), the American College of Clinical Pharmacology (ACCP), the Controlled Release Society (CRS) and the American Association for the Advancement of Science. In 1982, Dr. Benet received the American Pharmacists Association (APhA) Academy of Pharmaceutical Sciences (APS) Research Achievement Award in Pharmaceutics and the University of Michigan, College of Pharmacy, Distinguished Alumnus Award. In 1985, he served as President of APS. During 1986, Dr. Benet was a Founder and first President of the AAPS. In 1987, Dr. Benet was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences. In 1988, he received the ACCP Distinguished Service Award and in 1989, the initial AAPS Distinguished Pharmaceutical Scientist Award. In 1990, he was the recipient of the Rho Chi Lecture Award, and the UCSF Long Teaching Award, while in 1991, he received the Volwiler Research Achievement Award of the American Association of Colleges of Pharmacy (AACP). In 1993-94, he served as AACP President. In 1995, he received the Rawls-Palmer Progress in Medicine Award of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) and delivered the American College of Clinical Pharmacy “Therapeutic Frontiers Lecture”. In 1996, he received the AAPS Distinguished Service Award, and in 2000 the APhA Takeru Higuchi Research Prize and the AAPS Wurster Research Award in Pharmaceutics. In 2001 he was awarded the Høst-Madsen Medal of the International Pharmaceutical Federation (FIP) and the UCSF Outstanding Faculty Mentorship Award. In 2004, he was awarded the Pharmaceutical Sciences World Congress Research Achievement Award and the CRS Career Achievement in Oral Drug Delivery Award. In 2007 he was selected as the UCSF Distinguished Clinical Research Lecturer and is still the only non-MD so honored. In 2010, he received the ASCPT Hunter Memorial Award in Therapeutics and in 2011 the ACCP Distinguished Investigator award. In 2012, the September issue of PHARMACEUTICAL RESEARCH was dedicated in his honor under the title “50 Years of Scientific Excellence and Still Going Strong” and he was made an honorary member of FIP. In March 2013, he was awarded the APhA Ebert Prize and the September issue of JOURNAL OF PHARMACEUTICAL SCIENCES was dedicated in his honor. Dr. Benet formerly served as Chair of the Pharmacology Study Section and the Pharmacological Sciences Review Committee for the NIH, the FDA CBER Peer Review Committee, the FDA Expert Panel on Individual Bioequivalence, the Board of Pharmaceutical Sciences of the FIP, the Organizing Committee for the FIP Millennial World Congress of Pharmaceutical Sciences, the Congressionally mandated IOM/National Research Council (NRC) Committee on Accelerating the Research, Development and Acquisition of Medical Countermeasures Against Biological Warfare Agents and as a member of the FDA Generic Drugs Advisory Committee, the FDA Science Board and the NRC Biodefense Standing Committee. From 2007-2012 he served as Chair of the FIP Foundation for Education and Research. He presently serves on the Boards of Directors of the American Foundation for Pharmaceutical Education, Impax Laboratories, and Medicines360, of which the latter, he chairs. SEPTEMBER 2013

    Collapse Research 
    Collapse Research Activities and Funding
    A novel mechanistic modeling platform for predicting drug clearance and disposition mediated by transporters and enzymes
    NIH/NIGMS R43GM113597Jan 15, 2015 - Oct 14, 2015
    Role: Co-Principal Investigator
    A Transporter-Based Predictive ADME Platform
    NIH/NCRR R43RR031474May 15, 2010 - May 14, 2011
    Role: Principal Investigator
    Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
    NIH/NIGMS R21GM075900Jun 2, 2006 - May 31, 2009
    Role: Principal Investigator
    NIH/NICHD P01HD040543Apr 23, 2001 - Mar 31, 2008
    Role: Co-Investigator
    NIH/NIGMS R01GM057656Aug 1, 1997 - Jul 31, 2001
    Role: Co-Principal Investigator
    Proteases in Cancer Biology and Drug Development
    NIH/NCI P01CA072006Jun 10, 1997 - Jun 30, 2010
    Role: Co-Investigator
    NIH/NIGMS R01GM036633Apr 1, 1986 - Mar 31, 2004
    Role: Principal Investigator
    NIH/NIGMS U09GM007709Nov 1, 1984 - Jul 31, 1991
    Role: Co-Principal Investigator
    NIH/NHLBI R01HL032243Apr 1, 1984 - Dec 31, 1991
    Role: Principal Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator
    NIH/NIGMS P50GM026691Aug 1, 1979 - Jul 31, 1998
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chan R, Benet LZ. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification. Toxicol Res (Camb). 2018 May 08; 7(3):358-370. PMID: 29785262.
      View in: PubMed
    2. Benet LZ. Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. J Clin Pharmacol. 2018 Apr 17. PMID: 29663413.
      View in: PubMed
    3. Chan R, Benet LZ. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. Toxicol Sci. 2018 Apr 01; 162(2):499-508. PMID: 29272540.
      View in: PubMed
    4. Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S. A Drug-drug Interaction Between Cyclosporine and Nystatin. Clin Ther. 2018 Mar 15. PMID: 29551534.
      View in: PubMed
    5. Phung N, Kuncze K, Okochi H, Louie A, Benet LZ, Ofokotun I, Haas DW, Currier JS, Chawana TD, Sheth AN, Bacchetti P, Gandhi M, Horng H. Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2018 Mar 15; 32(5):431-441. PMID: 29315954.
      View in: PubMed
    6. Parasrampuria DA, Benet LZ, Sharma A. Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. AAPS J. 2018 Mar 13; 20(3):46. PMID: 29536211.
      View in: PubMed
    7. Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 Jan 08; 8(1):92. PMID: 29311658.
      View in: PubMed
    8. Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M. Comparison of Measures of Adherence to HIV Preexposure Prophylaxis among Adolescent and Young Men Who Have Sex with Men in the United States. Clin Infect Dis. 2017 Aug 24. PMID: 29020194.
      View in: PubMed
    9. Benet LZ, Wu HF. Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. J Pharm Sci. 2017 Sep; 106(9):2231-2233. PMID: 28502797.
      View in: PubMed
    10. Noguchi S, Nishimura T, Mukaida S, Benet LZ, Nakashima E, Tomi M. Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep; 106(9):2895-2898. PMID: 28385546.
      View in: PubMed
    11. Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. J Pharm Sci. 2017 Sep; 106(9):2751-2757. PMID: 28385543.
      View in: PubMed
    12. Chan R, Benet LZ. Evaluation of DILI Predictive Hypotheses in Early Drug Development. Chem Res Toxicol. 2017 04 17; 30(4):1017-1029. PMID: 28257576.
      View in: PubMed
    13. Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses. 2017 Mar 02. PMID: 28253024.
      View in: PubMed
    14. Faber KP, Wu HF, Yago MR, Xu X, Kadiyala P, Frassetto LA, Benet LZ. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. Pharm Res. 2017 Mar; 34(3):619-628. PMID: 28028768.
      View in: PubMed
    15. Li J, Larregieu CA, Benet LZ. Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Chin J Nat Med. 2016 Dec; 14(12):888-897. PMID: 28262115.
      View in: PubMed
    16. Burmeister Getz E, Carroll KJ, Mielke J, Benet LZ, Jones B. Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial. Clin Pharmacol Ther. 2017 Mar; 101(3):331-340. PMID: 27727445.
      View in: PubMed
    17. Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016 11; 3(11):e521-e528. PMID: 27658870.
      View in: PubMed
    18. Bowman CM, Benet LZ. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System. Drug Metab Dispos. 2016 11; 44(11):1731-1735. PMID: 27519549.
      View in: PubMed
    19. Benet LZ. 2016 Remington Honor Medal Address: Science for the profession. J Am Pharm Assoc (2003). 2016 Jul-Aug; 56(4):365-8. PMID: 27450136.
      View in: PubMed
    20. Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. Int J Tuberc Lung Dis. 2016 06; 20(6):844-7. PMID: 27155191.
      View in: PubMed
    21. Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev. 2016 Jun 01; 101:89-98. PMID: 27182629.
      View in: PubMed
    22. Burmeister Getz E, Carroll KJ, Jones B, Benet LZ. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial. Clin Pharmacol Ther. 2016 Sep; 100(3):223-31. PMID: 27037630.
      View in: PubMed
    23. Chan R, Wei CY, Chen YT, Benet LZ. Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. AAPS J. 2016 05; 18(3):757-66. PMID: 26951484.
      View in: PubMed
    24. Zheng Y, Chen X, Benet LZ. Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clin Pharmacokinet. 2016 Feb; 55(2):143-67. PMID: 26293617.
      View in: PubMed
    25. Hosey CM, Chan R, Benet LZ. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. AAPS J. 2016 Jan; 18(1):251-60. PMID: 26589308; PMCID: PMC4706282 [Available on 11/20/16].
    26. Garrison KL, Sahin S, Benet LZ. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS. J Pharm Sci. 2015 Sep; 104(9):3229-35. PMID: 26010239; PMCID: PMC4536115.
    27. Hosey CM, Benet LZ. Predicting the extent of metabolism using in vitro permeability rate measurements and in silico permeability rate predictions. Mol Pharm. 2015 May 04; 12(5):1456-66. PMID: 25816851; PMCID: PMC4666302.
    28. Zheng Y, Benet LZ, Okochi H, Chen X. pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. Pharm Res. 2015 Aug; 32(8):2516-26. PMID: 25690341; PMCID: PMC4891189.
    29. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. PMID: 25776193.
      View in: PubMed
    30. Parasrampuria DA, Benet LZ. Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful. Basic Clin Pharmacol Toxicol. 2015 Jul; 117(1):44-51. PMID: 25406995.
      View in: PubMed
    31. Yago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ding X, Dean B, Salphati L, Budha N, Jin JY, Dresser MJ, Ware JA. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J. 2014 Nov; 16(6):1358-65. PMID: 25274610; PMCID: PMC4389759.
    32. Hosey CM, Broccatelli F, Benet LZ. Predicting when biliary excretion of parent drug is a major route of elimination in humans. AAPS J. 2014 Sep; 16(5):1085-96. PMID: 25004821; PMCID: PMC4147063.
    33. Larregieu CA, Benet LZ. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm. 2014 Apr 07; 11(4):1335-44. PMID: 24628254; PMCID: PMC3983369.
    34. Frassetto LA, Tan-Tam CC, Barin B, Browne M, Wolfe AR, Stock PG, Roland M, Benet LZ. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. Transplantation. 2014 Mar 27; 97(6):702-7. PMID: 24389906; PMCID: PMC4018220.
    35. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014 Apr 03; 508(7494):93-7. PMID: 24572354; PMCID: PMC4161230.
    36. Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013 Nov 04; 10(11):4055-62. PMID: 24044612.
      View in: PubMed
    37. Estudante M, Maya M, Morais JG, Soveral G, Benet LZ. Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil. Mol Pharm. 2013 Nov 04; 10(11):4038-45. PMID: 24044638.
      View in: PubMed
    38. Frassetto L, Floren L, Barin B, Browne M, Wolfe A, Roland M, Stock P, Carlson L, Christians U, Benet L. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos. 2013 Nov; 34(8):442-51. PMID: 24030928; PMCID: PMC4018225.
    39. Yago MR, Frymoyer AR, Smelick GS, Frassetto LA, Budha NR, Dresser MJ, Ware JA, Benet LZ. Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. Mol Pharm. 2013 Nov 04; 10(11):4032-7. PMID: 23980906; PMCID: PMC3946491.
    40. Horng H, Benet LZ. The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bionucleophiles. Drug Metab Dispos. 2013 Nov; 41(11):1923-33. PMID: 23975029; PMCID: PMC3807055.
    41. Horng H, Benet LZ. Characterization of the acyl-adenylate linked metabolite of mefenamic Acid. Chem Res Toxicol. 2013 Mar 18; 26(3):465-76. PMID: 23402341; PMCID: PMC3626286.
    42. Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res. 2013 Apr; 30(4):932-50. PMID: 23417511; PMCID: PMC3640342.
    43. Larregieu CA, Benet LZ. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. AAPS J. 2013 Apr; 15(2):483-97. PMID: 23344793; PMCID: PMC3675726.
    44. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013 Jan; 102(1):34-42. PMID: 23147500; PMCID: PMC3684558.
    45. Benet LZ. A step closer to personalized chemotherapy: consideration of the influence of genetic variation in hepatic uptake transporters on the metabolism of CYP3A substrates. Clin Pharmacol Ther. 2012 Nov; 92(5):551-2. PMID: 23085879.
      View in: PubMed
    46. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 2013 Oct; 65(10):1340-56. PMID: 23041352.
      View in: PubMed
    47. Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012 Aug; 92(2):203-13. PMID: 22739140.
      View in: PubMed
    48. Benet LZ. Benet L Z and Galeazzi R L: noncompartmental determination of the steady-state volume of distribution, J Pharm Sci 68, 1071-1074, 1979--the backstory. AAPS J. 2012 Jun; 14(2):164-7. PMID: 22302585; PMCID: PMC3326156.
    49. Liu W, Okochi H, Benet LZ, Zhai SD. Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. Pharm Res. 2012 Jul; 29(7):1768-74. PMID: 22350803; PMCID: PMC4167886.
    50. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. BDDCS class prediction for new molecular entities. Mol Pharm. 2012 Mar 05; 9(3):570-80. PMID: 22224483; PMCID: PMC3295927.
    51. Broccatelli F, Larregieu CA, Cruciani G, Oprea TI, Benet LZ. Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan; 64(1):95-109. PMID: 22261306; PMCID: PMC3496430.
    52. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011 Sep; 31(9):871-6. PMID: 21923588; PMCID: PMC3727161.
    53. Grover A, Frassetto LA, Benet LZ, Chakkera HA. Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients. Drug Metab Dispos. 2011 Nov; 39(11):2017-9. PMID: 21849516; PMCID: PMC3198899.
    54. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011 Dec; 13(4):519-47. PMID: 21818695; PMCID: PMC3231854.
    55. Rowland M, Benet LZ. Lead PK commentary: predicting human pharmacokinetics. J Pharm Sci. 2011 Oct; 100(10):4047-9. PMID: 21630278.
      View in: PubMed
    56. Terasaki T, Sugiyama Y, Benet LZ. Professor Akira Tsuji: scientist, educator, and leader. J Pharm Sci. 2011 Sep; 100(9):3541-6. PMID: 21630279.
      View in: PubMed
    57. Reyes M, Benet LZ. Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci. 2011 Sep; 100(9):3831-42. PMID: 21618544; PMCID: PMC3581075.
    58. Grover A, Benet LZ. Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation. J Pharmacokinet Pharmacodyn. 2011 Jun; 38(3):369-83. PMID: 21499748; PMCID: PMC3677834.
    59. Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX. The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011 Jul; 28(7):1774-8. PMID: 21491148.
      View in: PubMed
    60. Park MS, Okochi H, Benet LZ. Is Ciprofloxacin a Substrate of P-glycoprotein? Arch Drug Inf. 2011 Mar; 4(1):1-9. PMID: 21572514.
      View in: PubMed
    61. Aarons L, Benet LZ. Founding figures of pharmacokinetics: tribute to Malcolm Rowland. J Pharmacokinet Pharmacodyn. 2010 Dec; 37(6):525-7. PMID: 21069561.
      View in: PubMed
    62. Benet LZ. Clearance (née Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn. 2010 Dec; 37(6):529-39. PMID: 21113650; PMCID: PMC3005114.
    63. Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011 Jan; 32(1):50-7. PMID: 21075140.
      View in: PubMed
    64. Frymoyer A, Shugarts S, Browne M, Wu AH, Frassetto L, Benet LZ. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010 Oct; 88(4):540-7. PMID: 20703222; PMCID: PMC3091944.
    65. Benet LZ, Larregieu CA. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther. 2010 Sep; 88(3):405-7. PMID: 20668447; PMCID: PMC4169211.
    66. Frymoyer A, Hersh AL, Coralic Z, Benet LZ, Joseph Guglielmo B. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther. 2010 Mar; 32(3):534-42. PMID: 20399990; PMCID: PMC3097025.
    67. Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar; 9(3):215-36. PMID: 20190787; PMCID: PMC3326076.
    68. Sun H, Frassetto LA, Huang Y, Benet LZ. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther. 2010 Apr; 87(4):465-72. PMID: 20090676; PMCID: PMC3581054.
    69. Grillo MP, Wait JC, Tadano Lohr M, Khera S, Benet LZ. Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes. Drug Metab Dispos. 2010 Jan; 38(1):133-42. PMID: 19786506; PMCID: PMC2802421.
    70. Benet LZ. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol. 2010 Mar; 106(3):162-7. PMID: 20002064; PMCID: PMC3564954.
    71. de Souza J, Benet LZ, Huang Y, Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci. 2009 Nov; 98(11):4413-9. PMID: 19472342.
      View in: PubMed
    72. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009 Nov-Dec; 6(6):1631-43. PMID: 19874004; PMCID: PMC2796475.
    73. Benet LZ. A Holy Grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient. Clin Pharmacol Ther. 2009 Aug; 86(2):133-4. PMID: 19621007.
      View in: PubMed
    74. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009 Sep; 26(9):2039-54. PMID: 19568696; PMCID: PMC2719753.
    75. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009 May; 28(5):398-402. PMID: 19295465; PMCID: PMC3101254.
    76. Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009 Jun; 11(2):250-61. PMID: 19399628; PMCID: PMC2691462.
    77. Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K, Wolfe AR, Young M, Cohen M, Minkoff H, Gange SJ, Greenblatt RM. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):482-91. PMID: 19408353; PMCID: PMC2700138.
    78. Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res. 2008 Dec; 25(12):2869-77. PMID: 19015955; PMCID: PMC3581066.
    79. Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009 Jan; 85(1):78-85. PMID: 18843263; PMCID: PMC3582657.
    80. Monera TG, Wolfe AR, Maponga CC, Benet LZ, Guglielmo J. Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Infect Dev Ctries. 2008 Oct 01; 2(5):379-83. PMID: 19745507.
      View in: PubMed
    81. Grillo MP, Hua F, March KL, Benet LZ, Knutson CG, Ware JA. Gamma-glutamyltranspeptidase-mediated degradation of diclofenac-S-acyl-glutathione in vitro and in vivo in rat. Chem Res Toxicol. 2008 Oct; 21(10):1933-8. PMID: 18693772.
      View in: PubMed
    82. Benet LZ, Amidon GL, Barends DM, Lennernäs H, Polli JE, Shah VP, Stavchansky SA, Yu LX. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res. 2008 Mar; 25(3):483-8. PMID: 18236138; PMCID: PMC3580995.
    83. Li C, Grillo MP, Badagnani I, Fife KL, Benet LZ. Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats. Drug Metab Dispos. 2008 Apr; 36(4):682-7. PMID: 18187563.
      View in: PubMed
    84. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olthoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008 Feb; 8(2):355-65. PMID: 18093266.
      View in: PubMed
    85. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008 Mar 17; 60(6):717-33. PMID: 18199522; PMCID: PMC2292816.
    86. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, Carlson L, Benet LZ. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007 Dec; 7(12):2816-20. PMID: 17949460.
      View in: PubMed
    87. Boernsen KO, Egge-Jacobsen W, Inverardi B, Strom T, Streit F, Schiebel HM, Benet LZ, Christians U. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom. 2007 Jun; 42(6):793-802. PMID: 17511017.
      View in: PubMed
    88. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther. 2007 Jun; 81(6):828-32. PMID: 17361125.
      View in: PubMed
    89. Olsen J, Li C, Skonberg C, Bjørnsdottir I, Sidenius U, Benet LZ, Hansen SH. Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats. Drug Metab Dispos. 2007 May; 35(5):758-64. PMID: 17303625.
      View in: PubMed
    90. Lau YY, Huang Y, Frassetto L, Benet LZ. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Feb; 81(2):194-204. PMID: 17192770.
      View in: PubMed
    91. Lam JL, Shugarts SB, Okochi H, Benet LZ. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther. 2006 Nov; 319(2):864-70. PMID: 16905688.
      View in: PubMed
    92. Lam JL, Okochi H, Huang Y, Benet LZ. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos. 2006 Aug; 34(8):1336-44. PMID: 16698890.
      View in: PubMed
    93. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006 Jul; 34(7):1175-81. PMID: 16624870.
      View in: PubMed
    94. Huang Y, Okochi H, May BC, Legname G, Prusiner SB, Benet LZ, Guglielmo BJ, Lin ET. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul; 34(7):1136-44. PMID: 16581945.
      View in: PubMed
    95. Huang Y, Sun H, Frassetto L, Benet LZ, Lin ET. Liquid chromatographic tandem mass spectrometric assay for the uremic toxin 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in human plasma. Rapid Commun Mass Spectrom. 2006; 20(10):1611-4. PMID: 16628600.
      View in: PubMed
    96. Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, McKerrow JH. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother. 2005 Dec; 49(12):5160-1. PMID: 16304193; PMCID: PMC1315979.
    97. Olsen J, Li C, Bjørnsdottir I, Sidenius U, Hansen SH, Benet LZ. In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. Chem Res Toxicol. 2005 Nov; 18(11):1729-36. PMID: 16300382.
      View in: PubMed
    98. Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther. 2006 Feb; 316(2):762-71. PMID: 16258024.
      View in: PubMed
    99. Chang JH, Benet LZ. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol Pharm. 2005 Sep-Oct; 2(5):428-34. PMID: 16196496.
      View in: PubMed
    100. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006 Jan; 109(1-2):1-11. PMID: 16085315.
      View in: PubMed
    101. Wetmore JB, Benet LZ, Kleinstuck D, Frassetto L. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton). 2005 Aug; 10(4):393-9. PMID: 16109088.
      View in: PubMed
    102. Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, Carlson L, Benet LZ. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation. 2005 Jul 15; 80(1):13-7. PMID: 16003227.
      View in: PubMed
    103. Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol. 2005 Apr; 45(4):411-21. PMID: 15778422.
      View in: PubMed
    104. Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv. 2005 Apr; 5(2):79-83. PMID: 15821156.
      View in: PubMed
    105. Benet L. Basic pharmacological interactions and how they may impact on one another. J Acquir Immune Defic Syndr. 2005 Mar; 38 Suppl 1:S22-3. PMID: 15867606.
      View in: PubMed
    106. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005 Jan; 22(1):11-23. PMID: 15771225.
      View in: PubMed
    107. Mohri K, Okada K, Benet LZ. Stereoselective taurine conjugation of (R)-benoxaprofen enantiomer in rats: in vivo and in vitro studies using rat hepatic mitochondria and microsomes. Pharm Res. 2005 Jan; 22(1):79-85. PMID: 15771233.
      View in: PubMed
    108. Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos. 2004 Nov; 32(11):1311-6. PMID: 15483198.
      View in: PubMed
    109. Ikeno F, Lyons J, Kaneda H, Baluom M, Benet LZ, Rezaee M. Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv. 2004 Oct; 63(2):222-30. PMID: 15390346.
      View in: PubMed
    110. Egge-Jacobsen W, Unger M, Niemann CU, Baluom M, Hirai S, Benet LZ, Christians U. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit. 2004 Oct; 26(5):546-62. PMID: 15385839.
      View in: PubMed
    111. Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, Serkova N. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol. 2004 Oct; 143(3):388-96. PMID: 15339861; PMCID: PMC1575349.
    112. Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004 Nov; 32(11):1239-46. PMID: 15286055.
      View in: PubMed
    113. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul; 21(7):1284-93. PMID: 15290871.
      View in: PubMed
    114. Frassetto LA, Benet LZ. Pharmacogenomics and transplantation: where are we? Am J Transplant. 2004 Jun; 4(6):843. PMID: 15147415.
      View in: PubMed
    115. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004 Apr; 4(2):97-107. PMID: 15087483.
      View in: PubMed
    116. Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther. 2004 Mar; 308(3):1040-5. PMID: 14634033.
      View in: PubMed
    117. Wu CY, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos. 2003 Nov; 31(11):1292-5. PMID: 14570757.
      View in: PubMed
    118. Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004 Jan; 308(1):143-55. PMID: 14569063.
      View in: PubMed
    119. Li C, Olurinde MO, Hodges LM, Grillo MP, Benet LZ. Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. Drug Metab Dispos. 2003 Jun; 31(6):727-30. PMID: 12756204.
      View in: PubMed
    120. Li C, Grillo MP, Benet LZ. In vivo mechanistic studies on the metabolic activation of 2-phenylpropionic acid in rat. J Pharmacol Exp Ther. 2003 Apr; 305(1):250-6. PMID: 12649376.
      View in: PubMed
    121. Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther. 2003 Apr; 305(1):306-14. PMID: 12649383.
      View in: PubMed
    122. Li C, Grillo MP, Benet LZ. In vitro studies on the chemical reactivity of 2,4-dichlorophenoxyacetyl-S-acyl-CoA thioester. Toxicol Appl Pharmacol. 2003 Mar 01; 187(2):101-9. PMID: 12649042.
      View in: PubMed
    123. Hebert MF, Wacher VJ, Roberts JP, Benet LZ. Pharmacokinetics of cyclosporine pre- and post-liver transplantation. J Clin Pharmacol. 2003 Jan; 43(1):38-42. PMID: 12520626.
      View in: PubMed
    124. Frassetto L, Thai T, Aggarwal AM, Bucher P, Jacobsen W, Christians U, Benet LZ, Floren LC. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet. 2003; 18(2):114-20. PMID: 15618725.
      View in: PubMed
    125. Putnam WS, Ramanathan S, Pan L, Takahashi LH, Benet LZ. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci. 2002 Dec; 91(12):2622-35. PMID: 12434407.
      View in: PubMed
    126. Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 2002 Dec; 68(12):1055-8. PMID: 12494328.
      View in: PubMed
    127. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002 Nov; 72(5):474-89. PMID: 12426511.
      View in: PubMed
    128. Li C, Benet LZ, Grillo MP. Enantioselective covalent binding of 2-phenylpropionic Acid to protein in vitro in rat hepatocytes. Chem Res Toxicol. 2002 Nov; 15(11):1480-7. PMID: 12437340.
      View in: PubMed
    129. Li C, Benet LZ, Grillo MP. Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem Res Toxicol. 2002 Oct; 15(10):1309-17. PMID: 12387630.
      View in: PubMed
    130. Niemann CU, Saeed M, Akbari H, Jacobsen W, Benet LZ, Christians U, Serkova N. Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther. 2002 Sep; 302(3):1123-8. PMID: 12183671.
      View in: PubMed
    131. Flanagan SD, Takahashi LH, Liu X, Benet LZ. Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. J Pharm Sci. 2002 Apr; 91(4):1169-77. PMID: 11948555.
      View in: PubMed
    132. Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr; 19(4):457-62. PMID: 12033380.
      View in: PubMed
    133. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002 Mar; 71(3):115-21. PMID: 11907485.
      View in: PubMed
    134. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. 2002 Mar; 300(3):1036-45. PMID: 11861813.
      View in: PubMed
    135. Serkova N, Donohoe P, Gottschalk S, Hainz C, Niemann CU, Bickler PE, Litt L, Benet LZ, Leibfritz D, Christians U. Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab. 2002 Mar; 22(3):342-52. PMID: 11891440.
      View in: PubMed
    136. Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol. 2002 Mar; 42(3):304-11. PMID: 11865967.
      View in: PubMed
    137. Unger M, Jacobsen W, Holzgrabe U, Benet LZ. Quantitative liquid chromatography-mass spectrometry determination of isatin in urine using automated on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 15; 767(2):245-53. PMID: 11885853.
      View in: PubMed
    138. Grillo MP, Benet LZ. Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro. Drug Metab Dispos. 2002 Jan; 30(1):55-62. PMID: 11744612.
      View in: PubMed
    139. Putnam WS, Pan L, Tsutsui K, Takahashi L, Benet LZ. Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters. Pharm Res. 2002 Jan; 19(1):27-33. PMID: 11837697.
      View in: PubMed
    140. Flanagan SD, Cummins CL, Susanto M, Liu X, Takahashi LH, Benet LZ. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology. 2002; 64(3):126-34. PMID: 11834888.
      View in: PubMed
    141. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41(11):813-51. PMID: 12190331.
      View in: PubMed